The U.S. Centers for Medicare and Medicaid Services (CMS) will continue the new technology add-on payment (NTAP) for T2 Biosystems' T2Bacteria panel for the 2021 fiscal year.
The extension allows U.S. hospitals treating sepsis patients who are covered by Medicare to remain eligible for an NTAP of $97.50 for the T2Bacteria panel. This payment covers 65% of the average cost of the test panel, which detects pathogens that cause sepsis, for eligible patients, according to the company.
